Onconova Therapeutics (NASDAQ: ONTX) Decreased to Hold at Zacks Investment Research

NASDAQ: ONTX was reduced by Zacks  from a “buy” rating to a “hold” score in a research note issued to financiers on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical firm. It concentrates on uncovering and also developing little molecule medicine prospects to treat cancer cells. The Firm‘s products under different phases of development consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Several various other equities research experts additionally just recently commented on the company. Noble Financial reissued a “acquire” ranking and issued a $11.00 price objective on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 and also set a “get” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. The business has a 50 day moving typical rate of $2.90 and also a two-hundred day relocating typical price of $4.16. The business has a market cap of $46.76 million, a P/E ratio of -1.82 as well as a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly profits results on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) earnings per share for the quarter, topping analysts’ consensus price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% and also an adverse internet margin of 8,294.27%. The firm had earnings of $0.06 million throughout the quarter, contrasted to the agreement estimate of $0.06 million. During the exact same quarter in the previous year, the firm uploaded ($ 0.45) EPS. En masse, research analysts anticipate that Onconova Therapeutics will upload -1.18 EPS for the current year.

A number of hedge funds have recently dealt shares of ONTX. GSA Funding Partners LLP acquired a brand-new setting in Onconova Therapeutics throughout the 3rd quarter worth $922,000. Hudson Bay Funding Management LP bought a new setting in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC got a new placement in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC got a brand-new placement in shares of Onconova Therapeutics in the third quarter worth $493,000. Lastly, Dimensional Fund Advisors LP acquired a new placement in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds as well as other institutional financiers own 13.36% of the firm’s stock.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which engages in the identification and also growth of oncology therapeutics. It concentrates on discovering as well as creating little molecule drug prospects to deal with cancer cells. The firm was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Obtain a cost-free duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

To find out more about research offerings from Zacks Investment Research, check out Zacks.com.

This immediate news alert was created by narrative science innovation as well as monetary data from Market in order to give visitors with the fastest and also most exact coverage. This tale was assessed by Market’s editorial group prior to magazine. 



Before you consider Onconova Therapeutics, you’ll intend to hear this.

Market monitors Wall Street’s top-rated as well as best doing research experts and the stocks they advise to their clients daily. Market has determined the 5 stocks that cover analysts are quietly murmuring to their clients to get currently prior to the more comprehensive market catches on … and Onconova Therapeutics had not been on the checklist.

While Onconova Therapeutics currently has a “Buy” rating among experts, top-rated analysts think these 5 stocks are better gets.

You may also like